Navigation Links
Orphan Drugs - Global Strategic Business Report
Date:12/4/2013

DUBLIN, December 4, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs) has announced the addition of the "Orphan Drugs - Global Strategic Business Report" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 113 companies including many key and niche players such as:

- AbbVie Inc.
- Actelion Pharmaceuticals Ltd.
- Amgen Inc.
- AstraZeneca plc
- Bayer HealthCare AG
- Biogen Idec Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Celgene Corporation
- CEL-SCI Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Serono International S.A.
- Novartis AG
- Pfizer Inc.
- Recordati S.p.A.
- Orphan Europe
- Sanofi SA
- Genzyme Corporation.


Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For more information visit http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
2. Agility-PSR Wins "Best Contract Research Organization" in the 2013 ROAR Awards at the 4th Annual World Orphan Drug Conference in Geneva
3. CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
4. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
5. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
6. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
7. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
8. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
9. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
10. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
11. Orphan Drugs for Cancer: R&D and Market 2013-2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):